[go: up one dir, main page]

CO5570684A2 - Composiciones de disgregacion intraoral organolepticamente aceptables - Google Patents

Composiciones de disgregacion intraoral organolepticamente aceptables

Info

Publication number
CO5570684A2
CO5570684A2 CO04028409A CO04028409A CO5570684A2 CO 5570684 A2 CO5570684 A2 CO 5570684A2 CO 04028409 A CO04028409 A CO 04028409A CO 04028409 A CO04028409 A CO 04028409A CO 5570684 A2 CO5570684 A2 CO 5570684A2
Authority
CO
Colombia
Prior art keywords
composition
pharmaceutically acceptable
solution
retarder
polymer
Prior art date
Application number
CO04028409A
Other languages
English (en)
Inventor
T Le Trang
C Ludwig Blake
Original Assignee
Pharmacia Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia Corp filed Critical Pharmacia Corp
Publication of CO5570684A2 publication Critical patent/CO5570684A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Physiology (AREA)
  • Rheumatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nutrition Science (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

1.- Una composición oral fast-melt que comprende: (a) un fármaco organolépticamente inaceptable de baja solubilidad en agua en una cantidad terapéuticamente eficaz, (b) al menos un retardador de la disolución farmacéuticamente aceptable, y (c) al menos un excipiente farmacéuticamente aceptable que presenta una disolución oral rápida;siendo la composición organolépticamente aceptable.2.- La composición de la reivindicación 1, en la que el "al menos un retardador de la disolución farmacéuticamente aceptable" es un polímero.3.- La composición de la reivindicación 2, en la que el polímero está presente en una cantidad total de aproximadamente 0,5% a aproximadamente 15% en peso.4.- La composición de la reivindicación 2, en la que el polímero está presente en una cantidad total de aproximadamente 1,0% a aproximadamente 5% en peso.5.- La composición de la reivindicación 1, en la que el "al menos un retardador de la disolución farmacéuticamente aceptable" se selecciona entre el grupo compuesto por etilcelulosa, hidroxipropilmetilcelulosa, polivinilpirrolidona, Eudragit® EP O y productos equivalentes de polimetacrilato, hidroxipropiletilcelulosa e hidroxipropilcelulosa.6.- La composición de la reivindicación 1, en la que el "al menos un retardador de la disolución farmacéuticamente aceptable" es Eudragit® EP O o un producto de polimetacrilato equivalente.7.- La composición de la reivindicación 1, en la que el "al menos un excipiente farmacéuticamente aceptable que presenta una disolución oral rápida" es un carbohidrato.8.- La composición de la reivindicación 1, en la que el "al menos un excipiente farmacéuticamente aceptable que presenta una disolución oral rápida" es un sacárido.9.- La composición de la reivindicación 1, en la que el "al menos un excipiente farmacéuticamente aceptable que presenta una disolución oral rápida" se selecciona entre el grupo compuesto por maltosa, maltitol, sorbitol, lactosa y manitol.
CO04028409A 2001-09-26 2004-03-26 Composiciones de disgregacion intraoral organolepticamente aceptables CO5570684A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US32535601P 2001-09-26 2001-09-26

Publications (1)

Publication Number Publication Date
CO5570684A2 true CO5570684A2 (es) 2005-10-31

Family

ID=23267542

Family Applications (2)

Application Number Title Priority Date Filing Date
CO04028410A CO5570659A2 (es) 2001-09-26 2004-03-26 Composiciones de valdecoxib de disgregacion intraoral
CO04028409A CO5570684A2 (es) 2001-09-26 2004-03-26 Composiciones de disgregacion intraoral organolepticamente aceptables

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CO04028410A CO5570659A2 (es) 2001-09-26 2004-03-26 Composiciones de valdecoxib de disgregacion intraoral

Country Status (25)

Country Link
US (1) US20030181501A1 (es)
EP (2) EP1490035A1 (es)
JP (2) JP2005506987A (es)
KR (2) KR20040044990A (es)
CN (2) CN1703203A (es)
AP (2) AP2004002998A0 (es)
AR (1) AR037239A1 (es)
BR (2) BR0212861A (es)
CA (2) CA2461044A1 (es)
CO (2) CO5570659A2 (es)
EA (2) EA200400357A1 (es)
EC (1) ECSP045029A (es)
GE (1) GEP20063856B (es)
HK (1) HK1079988A1 (es)
IL (2) IL160848A0 (es)
IS (2) IS7177A (es)
MA (2) MA27542A1 (es)
MX (2) MXPA04002798A (es)
NO (2) NO20041258L (es)
OA (2) OA13060A (es)
PL (2) PL369298A1 (es)
TN (2) TNSN04045A1 (es)
WO (2) WO2003026623A1 (es)
YU (1) YU34804A (es)
ZA (2) ZA200401953B (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005002557A1 (en) * 2003-07-03 2005-01-13 Warner-Lambert Company Llc Pharmaceutical compositions including an ether and selective cox-2 inhibitor and uses thereof
US20050186271A1 (en) * 2004-02-24 2005-08-25 Sheskey Paul J. Process for dispersing a fluid in a mass of solid particles
KR20130018956A (ko) * 2004-08-10 2013-02-25 아지노모토 가부시키가이샤 쓴맛이 감소된 나테글리니드 함유 제제
US20080063710A1 (en) * 2004-12-28 2008-03-13 Eisai R&D Management Co., Ltd. Rapidly Disintegrating Tablet and Production Method Thereof
US8497258B2 (en) 2005-11-12 2013-07-30 The Regents Of The University Of California Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract
CN101340899A (zh) * 2005-12-20 2009-01-07 卫材R&D管理有限公司 含有脂溶性药物的口腔内速崩片
US8252329B2 (en) 2007-01-05 2012-08-28 Acelrx Pharmaceuticals, Inc. Bioadhesive drug formulations for oral transmucosal delivery
US8202535B2 (en) 2006-01-06 2012-06-19 Acelrx Pharmaceuticals, Inc. Small-volume oral transmucosal dosage forms
US8865743B2 (en) 2006-01-06 2014-10-21 Acelrx Pharmaceuticals, Inc. Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain
US8535714B2 (en) 2006-01-06 2013-09-17 Acelrx Pharmaceuticals, Inc. Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain
US20090136570A1 (en) * 2006-01-20 2009-05-28 Bhagwant Rege Taste-Masked Tablets and Granules
US20070196494A1 (en) * 2006-02-17 2007-08-23 Arnaud Grenier Low-friability, patient-friendly orally disintegrating formulations
EP2026792A2 (en) * 2006-05-19 2009-02-25 Somaxon Pharmaceuticals, Inc. Low dose doxepin formulations, including buccal, sublingual and fastmelt formulations, and uses of the same to treat insomnia
EP2164461B1 (de) * 2007-06-06 2013-01-23 Basf Se Kau- und lutsch-tabletten
CN102046147B (zh) * 2007-06-06 2013-03-20 巴斯夫欧洲公司 用于制备快速崩解的片剂的药物配制剂
ES2646112T3 (es) * 2007-06-06 2017-12-12 Basf Se Formulación farmacéutica para la fabricación de comprimidos que se desintegran rápidamente
CN101707930B (zh) * 2007-06-06 2013-10-30 巴斯夫欧洲公司 用于制备快速崩解的片剂的药物配制剂
KR101606944B1 (ko) * 2007-08-07 2016-03-28 아셀알엑스 파마슈티컬스 인코퍼레이티드 경구 경점막 투여형을 사용한 시술시 진정과 무통을 위한 조성물 및 방법
WO2009118589A2 (en) 2008-03-24 2009-10-01 Wockhardt Research Centre Orally disintegrating compositions of rhein or diacerein
US8945592B2 (en) * 2008-11-21 2015-02-03 Acelrx Pharmaceuticals, Inc. Sufentanil solid dosage forms comprising oxygen scavengers and methods of using the same
WO2010061846A1 (ja) * 2008-11-25 2010-06-03 田辺三菱製薬株式会社 口腔内速崩壊性錠及びその製造方法
EP2440210A4 (en) 2009-06-12 2014-01-29 Meritage Pharma Inc METHOD FOR THE TREATMENT OF STOMACH DARM DISEASES
US20110091544A1 (en) * 2009-10-16 2011-04-21 Acelrx Pharmaceuticals, Inc. Compositions and Methods for Mild Sedation, Anxiolysis and Analgesia in the Procedural Setting
FR2968995B1 (fr) * 2010-12-16 2013-03-22 Sanofi Aventis Composition pharmaceutioue pour une administration par voie orale destinee a eviter le mesusage
CN106822007B (zh) 2015-09-11 2021-12-31 西姆莱斯股份公司 口服制剂

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5474995A (en) * 1993-06-24 1995-12-12 Merck Frosst Canada, Inc. Phenyl heterocycles as cox-2 inhibitors
US5576014A (en) * 1994-01-31 1996-11-19 Yamanouchi Pharmaceutical Co., Ltd Intrabuccally dissolving compressed moldings and production process thereof
US5633272A (en) * 1995-02-13 1997-05-27 Talley; John J. Substituted isoxazoles for the treatment of inflammation
IN182040B (es) * 1995-06-13 1998-12-12 American Home Prod
PT855988E (pt) * 1995-10-20 2002-10-31 Upjohn Co Embalagem de bolhas
JPH11512754A (ja) * 1996-05-17 1999-11-02 メルク エンド カンパニー インコーポレーテッド シクロオキシゲナーゼ―２媒介疾患の一日一回治療用組成物
EP0863134A1 (en) * 1997-03-07 1998-09-09 Merck Frosst Canada Inc. 2-(3,5-difluorophenyl)-3-(4-(methyl-sulfonyl)phenyl)-2-cyclopenten-1-one useful as an inhibitor of cyclooxygenase-2
US6465009B1 (en) * 1998-03-18 2002-10-15 Yamanouchi Pharmaceutical Co., Ltd. Water soluble polymer-based rapidly dissolving tablets and production processes thereof
BR0008059A (pt) * 1999-12-08 2002-03-26 Pharmacia Corp Composições de valdecoxib
US6316029B1 (en) * 2000-05-18 2001-11-13 Flak Pharma International, Ltd. Rapidly disintegrating solid oral dosage form
US6800297B2 (en) * 2000-06-15 2004-10-05 Acusphere, Inc. Porous COX-2 inhibitor matrices and methods of manufacture thereof
CN1638739A (zh) * 2000-08-18 2005-07-13 法玛西雅厄普约翰美国公司 治疗成瘾性障碍的化合物
AU2001285011A1 (en) * 2000-08-18 2002-03-04 Pharmacia Corporation Rapidly disintegrating oral formulation of a cyclooxygenase-2 inhibitor

Also Published As

Publication number Publication date
TNSN04045A1 (fr) 2006-06-01
OA13060A (en) 2006-11-10
BR0212778A (pt) 2004-12-07
CO5570659A2 (es) 2005-10-31
WO2003026623A8 (en) 2004-09-30
EP1490035A1 (en) 2004-12-29
WO2003026697A2 (en) 2003-04-03
AP2004002998A0 (en) 2004-03-31
PL369298A1 (en) 2005-04-18
IL160855A0 (en) 2004-08-31
EA200400357A1 (ru) 2004-08-26
EP1429736A2 (en) 2004-06-23
MA27542A1 (fr) 2005-10-03
GEP20063856B (en) 2006-06-26
MA27682A1 (fr) 2006-01-02
MXPA04002798A (es) 2004-07-05
JP2005506987A (ja) 2005-03-10
YU34804A (sh) 2006-08-17
NO20041258L (no) 2003-03-27
CA2461630A1 (en) 2003-04-03
KR20040044990A (ko) 2004-05-31
HK1079988A1 (zh) 2006-04-21
IL160848A0 (en) 2004-08-31
NO20041532L (no) 2004-04-15
KR20040058189A (ko) 2004-07-03
WO2003026623A1 (en) 2003-04-03
MXPA04002652A (es) 2004-06-07
PL369297A1 (en) 2005-04-18
CN1703203A (zh) 2005-11-30
IS7177A (is) 2004-03-11
EA200400352A1 (ru) 2004-12-30
JP2005512964A (ja) 2005-05-12
OA12707A (en) 2006-06-26
BR0212861A (pt) 2004-10-05
TNSN04047A1 (fr) 2006-06-01
US20030181501A1 (en) 2003-09-25
AP2004002999A0 (en) 2004-03-31
ECSP045029A (es) 2004-04-28
ZA200401953B (en) 2005-05-09
AR037239A1 (es) 2004-11-03
IS7178A (is) 2004-03-11
ZA200402364B (en) 2005-01-13
CA2461044A1 (en) 2003-04-03
WO2003026697A3 (en) 2003-07-03
CN1633281A (zh) 2005-06-29

Similar Documents

Publication Publication Date Title
CO5570684A2 (es) Composiciones de disgregacion intraoral organolepticamente aceptables
EP2392326B1 (en) Silibinin component for the treatment of hepatitis
AR035927A1 (es) Compuesto de lactama (n)-((s)-2-hidroxi-3-metilbutiril)-1-(l-alaninil)-(s)-1-amino-3-metil-4,5,6,7-tetrahidro-2h-3-benzazepin-2-ona , composicion farmaceutica que lo comprende, procedimiento para la inhibicion de la liberacion de peptido b-amiloide y/o su sintesis que lo emplea y su uso para la fabr
WO2003047519A3 (en) 'compressed annular tablet with molded triturate tablet for oral and intraoral'
CO4940403A1 (es) Formulaciones de liberacion prolongada de derivados de eri- tromicina
CO5280073A1 (es) Composiciones
MY142204A (en) Pramipexole once-daily dosage form
IT1245761B (it) Formulazioni farmaceutiche contenenti glicosaminoglicani assorbibili per via orale.
SE8304393L (sv) Naproxen- och naproxennatriumtabletter av controlled release-typ
ITMI20001732A1 (it) Composizioni farmaceutiche per il trattamento di mucositi e stomatiti
BR0010485A (pt) Formulações de derivados de eritromicina de liberação prolongada
AR027034A1 (es) Composicion para dosis oral de liberacion extendida
LU90392I2 (fr) Une combination comprenant du salmeterol facultativement sous la forme d'un sel pharmaceutiquement acceptable y compris le 1-hydroxy-2-naphtoate (xinafoate) et le propionate de fluticasone
JP2005506987A5 (es)
AP2003002763A0 (en) Controlled release formulations for oral administration
US5753712A (en) Treatment of migraine headaches and formulations
CA2411882A1 (en) Solid valsartan pharmaceutical compositions
ES2115616T3 (es) Utilizacion de inositoltrisfosfato en la preparacion de medicamentos.
JP2001526234A5 (es)
MXPA04001933A (es) Composicion farmaceutica que comprende lumiracoxib.
BR0013719A (pt) Dosagem oral de liberaçâo controlada, apropriada para administração oral
DE68909100D1 (de) Physiologisch wirkende Substanzen, Verfahren zu ihrer Herstellung und pharmazeutische Zusammensetzungen davon.
BR0311642A (pt) Formulação de divalproex de sódio de liberação aumentada
HUP0203148A2 (hu) Mirtazapint tartalmazó orálisan dezintegrálódó készítmény
WO2001074396A8 (en) Composition and method for promoting oral health

Legal Events

Date Code Title Description
FC Application refused